Tivic Health Systems

Tivic Health Systems R&D per Employee

The R&D Spending per Employee of Tivic Health Systems (TIVC) as of Nov 1, 2026 is 195,687.50 USD. In the previous year, R&D Spending per Employee was 82,062.50 USD — a change of 138.46% (higher).

R&D per Employee

195,687.50USD

YoY

138.46%

Last updated:

R&D Spending per Employee of Tivic Health Systems is 2025 195,687.50 USD. R&D Spending per Employee of Tivic Health Systems was 2024 82,062.50 USD. It decreases by 138.46% higher compared to the previous year.

The Tivic Health Systems R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
61,875.00 USD
Jan 1, 2020
41,187.50 USD
Jan 1, 2021
54,875.00 USD
Jan 1, 2022
108,125.00 USD
Jan 1, 2023
103,437.50 USD
Jan 1, 2024
82,062.50 USD
Jan 1, 2025
195,687.50 USD
The Tivic Health Systems R&D per Employee history
YEARR&D per EmployeeYoY
195,687.50USD+138.46%
82,062.50USD-20.66%
103,437.50USD-4.34%
108,125.00USD+97.04%
54,875.00USD+33.23%
41,187.50USD-33.43%
61,875.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tivic Health Systems Stock analysis

What does Tivic Health Systems do? Tivic Health Systems Inc is a commercial-stage health tech company advancing bioelectronic medicine with patented technology that stimulates trigeminal, sympathetic, and vagus nerve structures. Its first commercial product, ClearUP, is an FDA-approved handheld bioelectronic sinus device clinically proven and doctor-recommended for treating inflammatory chronic conditions. ClearUP is sold directly to consumers in the U.S. through online retailers and commercial distributors, with reseller channels expanding its market reach. The company focuses on expanding its intellectual property portfolio and research programs related to vagus nerve stimulation for broader therapeutic applications. ClearUP serves consumers seeking drug-free therapeutic solutions for sinus conditions, targeting individuals with inflammatory chronic health issues who prefer non-invasive treatments. Healthcare providers recommend ClearUP as a safe, low-risk alternative to medication, appealing to patients looking for high safety profiles in treatment options. The company's revenue streams derive from direct consumer sales and reseller partnerships, leveraging its FDA approval and clinical validation to drive market adoption. Tivic Health Systems develops its products around non-invasive nerve stimulation technology, with ClearUP being the primary revenue-generating product. The company's strategy centers on expanding its IP portfolio to support future product development in bioelectronic medicine, particularly in vagus nerve stimulation applications. By focusing on clinical validation and doctor recommendations, Tivic Health aims to position itself as a leader in drug-free therapeutic solutions for chronic inflammatory conditions. Tivic Health Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tivic Health Systems stock

R&D Spending per Employee of Tivic Health Systems is 195,687.50 USD in 2025.

R&D Spending per Employee of Tivic Health Systems changed from 82,062.50 USD to 195,687.50 USD, representing a 138.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Tivic Health Systems since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Tivic Health Systems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Tivic Health Systems

All Key Metrics — Tivic Health Systems